Everyone talks about adding NAD⁺ — precursors, NMN, more fuel. Almost nobody talks about the drain. But a single enzyme, CD38, destroys NAD⁺ faster and faster as you age, driven by inflammation. If you're filling a leaking tank, more fuel isn't the answer — plugging the leak is.
The standard story of NAD⁺ decline is that you make less of it as you age. That's true — but it's only half the story, and the missing half changes the whole strategy. The other half is that you destroy more of it. A NAD⁺-consuming enzyme called CD38 rises steadily with age, chewing through your NAD⁺ pool ever faster — and it's now considered one of the major drivers of age-related NAD⁺ loss. This reframes everything: if the problem isn't the fuel pump but a growing leak in the tank, then pouring in more precursor is fighting the wrong battle. Let's see how CD38 drains your NAD⁺, why that makes precursors underperform, how to actually slow the leak — and why SS-31, despite living in the same "mitochondrial" conversation, has nothing to do with it.
CD38 is an enzyme found on immune cells and throughout many tissues, and its relevant job here is simple and destructive: it consumes NAD⁺. It's one of the body's largest NAD⁺-degrading enzymes — it breaks NAD⁺ down (using it for calcium-signaling and immune functions). So the crucial distinction: CD38 doesn't block NAD⁺ production — it destroys NAD⁺ that already exists. It's a leak in the tank, not a fault in the fuel pump. And it can even degrade the precursors (like NMN) before they become NAD⁺ — draining the supply line as well as the tank.
Here's the part that ties CD38 to your whole platform. CD38 activity rises with age — and the reason it rises is chronic low-grade inflammation (your "inflammaging" thread). As you accumulate inflammation and senescent cells over the years, the inflammatory signals they release drive more CD38 expression (especially on immune cells like macrophages). More inflammation → more CD38 → more NAD⁺ destroyed. So age-related NAD⁺ decline isn't mainly a supply problem — it's substantially a consumption problem, downstream of inflammation.
This is the mechanistic answer to "why did my NMN do nothing?" If CD38 is aggressively consuming NAD⁺ (and degrading the precursor), pouring in more NMN is filling a leaking bucket — the supply may never be the limiting factor. It reframes the whole NAD⁺ question: for many people, the leverage isn't adding fuel, it's slowing the drain. Supply-side thinking misses the leak entirely.
Because CD38 sits downstream of inflammation, the most durable approach is to address the root — with a more speculative direct-inhibition layer on top:
Since inflammation induces CD38, the anti-inflammatory work you're already mapping indirectly shrinks the leak: gut-barrier health, glutathione (GlyNAC), omega-3s, and generally lowering the inflammatory load. This is the "fix the root" route — CD38 is partly a symptom of inflammaging.
Senescent cells are a major source of the inflammatory signals that drive CD38. Senolytics (fisetin, quercetin) may indirectly help by removing that signal — and notice this lands squarely on your recurring cleanup / senescence gap. CD38 is yet another reason that gap matters.
The most-discussed natural candidate is apigenin (a flavonoid in parsley, celery, chamomile), with some CD38-inhibiting activity in research; quercetin and other flavonoids have been explored too, and research-grade pharmaceutical inhibitors exist. Honest tier: plausible mechanism, thin human proof — interesting frontier, not an established protocol.
Plug the leak before (or alongside) adding fuel. The complete picture is three-part: supply (precursors, if you're actually low), flow (help the chain run), and — the missing piece most people skip — stop the drain (lower inflammation, clear senescence, possibly inhibit CD38). Adding fuel to a leaking tank is the most common NAD⁺ mistake.
It's a natural question because SS-31 lives in the same "mitochondrial optimization" world — but SS-31 and CD38 address completely different problems, and conflating them is exactly the kind of mix-up this university exists to prevent:
An enzyme that consumes NAD⁺ — a problem of NAD⁺ destruction. Fixing it means slowing consumption (inflammation, senescence, inhibitors).
A structure-protector. It binds cardiolipin, the lipid of the inner mitochondrial membrane, stabilizing the membrane architecture so the electron chain stays organized and leaks fewer electrons. It protects the physical machine — nothing to do with NAD⁺ consumption.
SS-31 protects the machine's structure; CD38 inhibition plugs a fuel leak. They don't intersect — SS-31 won't slow the CD38 drain, and CD38 inhibition won't do SS-31's membrane-stabilizing job. (This is the "structure-protector vs carrier" distinction from the Mitochondrial Agents Compared map.) Both are legitimate — they just answer different questions. Precision here is the whole point: "mitochondrial support" is not one thing.
NAD⁺ falls with age not just because you make less, but because CD38 destroys more — a growing leak driven by inflammation and senescent cells, which also explains why precursors like NMN can underperform (you're filling a leaking tank). The fix is to slow the drain (lower inflammation, clear senescence, maybe inhibit CD38 with apigenin) as much as to add supply. And SS-31 doesn't help here — it protects mitochondrial structure (cardiolipin), a different problem entirely.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. CD38 biology and CD38-inhibition for NAD⁺ preservation are active research areas with limited human clinical proof; compounds like apigenin, quercetin, and fisetin have variable evidence and can interact with medications. SS-31 (elamipretide) is investigational. NAD⁺ metabolism interacts with methylation and inflammation in complex ways. Nothing here recommends a specific product, dose, or regimen; decisions belong with a qualified physician who can order appropriate testing and knows your full history.
This lesson relates to these health systems — health works as a connected system, not isolated topics.
Prerequisite: The Mitochondrial Map of the Body